Abstract:Allergic rhinitis is a non-infectious inflammatory disease of nasal mucosa mediated by immunoglobulin E, which involves a variety of immune cells, cytokines and inflammatory mediators. Inflammation of the nasal mucosa is one of the important pathological mechanisms of allergic rhinitis. The activation of NLRP3(NOD-like receptor protein 3, NLRP3) inflammasome induces the maturation and transformation of caspase-1 precursor, promotes the expression of inflammatory cytokines interleukin-1β(IL-1β) and interleukin-18(IL-18), participates in the inflammatory cascade reaction of allergic rhinitis, and promotes the occurrence and development of allergic rhinitis. The application of NLRP3 inflammasome related inhibitors can inhibit the expression of downstream inflammatory cytokines and alleviate the symptoms of allergic rhinitis. This article summarizes the related research on the regulation mechanism of NLRP3 Inflammasomes in allergic rhinitis and NLRP3 inflammasome-related pathway inhibitors suitable for the treatment of allergic rhinitis.